<DOC>
	<DOCNO>NCT00873093</DOCNO>
	<brief_summary>This pilot , phase II trial study side effect give bortezomib together combination chemotherapy see well work treat young patient relapse acute lymphoblastic leukemia lymphoblastic lymphoma . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Bortezomib Combination Chemotherapy Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate toxicity , second complete response ( CR2 ) rate end Block 1 therapy , 4-month event-free survival ( EFS ) pediatric young adult patient relapse acute lymphoblastic leukemia ( ALL ) treat bortezomib combination intensive re-induction chemotherapy . II . To evaluate bortezomib pharmacokinetics ( PK ) patient receive combination regimen . SECONDARY OBJECTIVES : I . To assess minimal residual disease ( MRD ) bone marrow follow completion therapy block . II . To assess feasibility measure leukemia initiate cell ( LIC ) patient sample chemotherapy . III . To discover biologic pathway associate response drug resistance use gene protein expression profile baseline follow initial exposure chemotherapy . IV . To determine bortezomib inhibits lymphoblast nuclear factor ( NF ) -kappa ( k ) -B activity leukemia patient . OUTLINE : REINDUCTION BLOCK 1 : Patients receive cytarabine intrathecally ( IT ) day 1 ; vincristine sulfate IV 1 minute day 1 , 8 , 15 , 22 ; doxorubicin hydrochloride IV 15 minute day 1 ; prednisone orally ( PO ) twice daily ( BID ) day 1-28 ; bortezomib IV 3-5 second day 1 , 4 , 8 , 11 ; pegaspargase intramuscularly ( IM ) IV 1-2 hour day 2 , 8 , 15 , 22 . Patients central nervous system ( CNS ) -negative disease ( CNS1 CNS2 ) also receive methotrexate IT day 15 29 ; patient CNS-positive disease ( CNS3 ) receive triple intrathecal therapy ( TIT ) comprise methotrexate , hydrocortisone , cytarabine IT day 8 , 15 , 22 , 29 . After completion reinduction block 1 , patient ALL M2 M3 bone marrow proceed directly reinduction block 2 . Patients ALL M1 bone marrow lymphoblastic lymphoma proceed reinduction block 2 blood count recover . Patients persistent cerebral spinal fluid ( CSF ) blast 6 dos TIT patient progressive lymphoblastic lymphoma remove study . REINDUCTION BLOCK 2 : Patients receive etoposide phosphate IV 1-2 hour day 1-5 ; cyclophosphamide IV 15-30 minute day 1-5 ; bortezomib IV 3-5 second day 1 , 4 , 8 ; filgrastim ( G-CSF ) subcutaneously ( SC ) IV daily begin day 6 continue blood count recover* ; high-dose methotrexate IV 24 hour day 22 ; leucovorin calcium PO IV every 6 hour day 23 24 . Patients CNS-negative disease also receive methotrexate IT day 1 22 ; patient CNS-positive disease receive TIT day 1 22 . After completion reinduction block 2 , patient proceed reinduction block 3 immediately blood count recover . Patients disease progression remove study . NOTE : *Patients receive G-CSF day 8 . REINDUCTION BLOCK 3 : Patients receive cytarabine IV 3 hour BID day 1 , 2 , 8 , 9 ; L-asparaginase IM day 2 9 ; G-CSF SC IV daily begin day 10 continue blood count recover . After completion study treatment , patient follow every 6 month 3 year annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Diagnosis PreB ALL first early ( &lt; 36 month diagnosis ) isolate bone marrow ( BM ) combine BM/extramedullary relapse ; Tcell ALL first isolate BM combine relapse ; TLL first relapse Patients leukemia must histologic verification malignancy relapse , include immunophenotyping confirm diagnosis Patients lymphoblastic lymphoma must measurable disease documented clinical , radiographic , histologic criterion ; patient must relapse become refractory conventional therapy Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age Patients relapse receive standard ALL maintenance chemotherapy require waiting period entry onto study Patients relapse therapy standard ALL maintenance therapy must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study At least 14 day since completion cytotoxic therapy exception hydroxyurea , permit 24 hour prior start protocol therapy At least 7 day since completion therapy biologic agent donor lymphocyte infusion ( DLI ) ; agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur No evidence active graftvshost disease ( GVHD ) &gt; = 4 month must elapse ; must receive GVHD prophylaxis Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month ( 0.4 male , 0.4 female ) 6 month &lt; 1 year ( 0.5 male , 0.5 female ) 1 &lt; 2 year ( 0.6 male , 0.6 female ) 2 &lt; 6 year ( 0.8 male , 0.8 female ) 6 &lt; 10 year ( 1 male , 1 female ) 10 &lt; 13 year ( 1.2 male , 1.2 female ) 13 &lt; 16 year ( 1.5 male , 1.4 female ) &gt; = 16 year ( 1.7 male , 1.4 female ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 3 x ULN age , unless elevation due leukemia infiltration Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % gate radionuclide study No evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; = 94 % sea level ( &gt; 90 % high altitude ) No evidence acute pulmonary infiltrates chest radiograph Patients seizure disorder may enrol allow anticonvulsant well control ; benzodiazepine gabapentin acceptable Central nervous system ( CNS ) toxicity = &lt; grade 2 Peripheral nervous system ( PNS ) toxicity &lt; grade 3 All patient and/or parent legal guardian must sign write informed consent All institutional , FDA , National Cancer Institute ( NCI ) requirement human study must meet Patients Philadelphia chromosome positive ALL eligible unless refractory least one tyrosine kinase inhibitor ( TKI ) therapy ; patient unable tolerate TKI therapy due toxicity eligible Patients mature Bcell ALL , ie , leukemia Bcell ( soluble immunoglobulin [ sIg ] positive kappa lambda restrict positivity ) ALL , FrenchAmericanBritish ( FAB ) L3 morphology and/or myc translocation , eligible Extramedullary disease status : patient isolated CNS disease isolate testicular disease eligible Patients know optic nerve and/or retinal involvement eligible ; patient present visual disturbance ophthalmological exam , indicate , magnetic resonance imaging ( MRI ) determine optic nerve retinal involvement Patients concomitant genetic syndrome : patient Down syndrome , Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome eligible Cumulative prior anthracycline exposure must exceed 400 mg/m^2 Patients take anticonvulsant know activate cytochrome p450 system , particular anticonvulsant phenytoin , carbamazepine , phenobarbital , eligible ; benzodiazepine gabapentin acceptable Patients previously receive bortezomib proteasome inhibitor eligible Patients know allergy doxorubicin , cytarabine , etoposide etopophos , boron , mannitol bortezomib eligible Patients receive asparaginase product ( E. Coli , PEGasparaginase , Erwinia asparaginase ) study ( eg , due prior severe pancreatitis , stroke toxicity ) eligible ; patient initially receive asparaginase , must discontinue due toxicity , remain eligible ; patient clinically significant prior allergy pegaspargase eligible Erwinia Lasparaginase substitute Patients pregnant breastfeed eligible study ; negative pregnancy test must obtain girl postmenarchal ; male female reproductive potential may participate unless agree use effective birth control method Patients must receive prior reinduction attempt must receive treatment prior extramedullary relapse ; patient primary induction failure eligible</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>